MATINAS BIOPHARMA HOLDINGS, INC.

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on redefining the intracellular delivery of nucleic acids and small molecules through its lipid nanocrystal (LNC) drug delivery platform. The Company is engaged in developing LYPDISO, as well as its LNC platform delivery technology and a pipeline of associated product candidates, including MAT2203 and MAT2501. Its LNC platform is designed to deliver a range of medicines, including small molecules, drugs with blood level-limiting toxicities, nucleic acid polymers, proteins, peptides, vaccines, and gene editing technologies. LYPDISO is a prescription-only omega-3 fatty acid-based composition, comprised primarily of eicosapentanoic acid (EPA) and docosapentanoic acid (DPA), intended for the treatment of cardiovascular and metabolic conditions. MAT2203 is an oral and non-toxic encochleated form of amphotericin B (CAmB). MAT2501 is an LNC formulation of the gram-negative antibiotic agent amikacin.